CN1481876A - Medication for virus hepatitis and hepatocirrhosis - Google Patents
Medication for virus hepatitis and hepatocirrhosis Download PDFInfo
- Publication number
- CN1481876A CN1481876A CNA031354785A CN03135478A CN1481876A CN 1481876 A CN1481876 A CN 1481876A CN A031354785 A CNA031354785 A CN A031354785A CN 03135478 A CN03135478 A CN 03135478A CN 1481876 A CN1481876 A CN 1481876A
- Authority
- CN
- China
- Prior art keywords
- radix
- medicine
- liver
- mushroom
- viral hepatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The medicine for treating viral hepatitis and hepatocirrhosis is prepared with red sage, mushroom, glossy ganoderma, aweto, eucommia bark, flax oil and other nine kinds of Chinese medicinal materials. It has high curative effect, wide indication range, no toxicity, no side effect and no damage to liver.
Description
Technical field:
The present invention is relevant with the medicine of treatment viral hepatitis, liver cirrhosis disease.
Background technology:
Natural drug treatment liver cirrhosis disease and chronic hepatitis diseases such as utilization Chinese herbal medicine are studied for many years always and are explored.The traditional Chinese medical science to the understanding of liver cirrhosis mainly is: due to illness do not heal for a long time, irritability lose to be dredged, venation discord, damp and hot strongly fragrant for a long time, liver spleen two wounds, qi depression to blood stasis, retention of water-damp in the body, liver body are lost and supported for a long time withered hardening.Treatment to be supporting spleen, and through clinical verification Chinese medicine, as: Radix Bupleuri, the Radix Paeoniae Alba, Radix Angelicae Sinensis, Radix Salviae Miltiorrhizae, PINGDIMU, Radix Pseudostellariae, the Rhizoma Atractylodis Macrocephalae, Semen Coicis, Rhizoma Dioscoreae, the Radix Astragali, Herba Taraxaci, Pericarpium Arecae, moxibustion Endothelium corneum plus-minus.Epistaxis, gingival hemorrhage, red tongue add the Radix Rehmanniae, Rhizoma Imperatae, Radix Notoginseng, Radix Paeoniae Rubra, Cortex Moutan.Hematemesis, have blood in stool, add Rhizoma Bletillae powder, the water transfer of Radix Notoginseng powder equivalent is taken.Hepatosplenomegaly adds Squama Manis, Fructus Akebiae, rhizoma sparganic, Rhizoma Curcumae, reuses Radix Salviae Miltiorrhizae.Enlarged abdomen such as drum, add Pericarpium Arecae, Lagenaria siceraria(Molina) Standl.var.depressa Ser., Herba Lobeliae Chinensis, Herba Verbenae, Herba Lycopi, Rhizoma Alismatis or use Pill for Relieving Ascites.Hepatic coma adds cow-bezoar bolus for resurrection, Zhibao Dan, XINGNAOJING.Low albumen can be used conditioning albumen such as Colla Corii Asini, Placenta Hominis, the Rhizoma Atractylodis Macrocephalae, Radix Codonopsis, Carapax et Plastrum Testudinis, Rhizoma Polygonati.Raise immunity, most with the kidney invigorating, Qi-tonifying drug: Radix Ginseng, the Radix Astragali, the Rhizoma Atractylodis Macrocephalae, Radix Morindae Officinalis, Rhizoma Polygonati, Herba Epimedii, Cordyceps, Fructus Lycii, Radix Polygoni Multiflori, Herba Cistanches etc.Suppress immunologic function, based on heat-clearing and toxic substances removing, as Herba Hedyotidis Diffusae, Rhizoma Polygoni Cuspidati etc.Fibrosis mostly is blood circulation promoting and blood stasis dispelling, collateral dredging softening the hard mass medicine, as Radix Angelicae Sinensis, Radix Salviae Miltiorrhizae, Flos Carthami, Radix Notoginseng, stir-baked SQUAMA MANITIS, Carapax Trionycis, rhizoma sparganic, Rhizoma Curcumae, Herba Sidae Rhombifoliae granule, Radix Et Rhizoma Rhei
Worm ball, shell liver softening tablet etc.
Different symptoms classification therapeutic purposes screening in the natural medicinal materials of above-mentioned a large amount of animals and plants, combination Pharmaceutical composition, of a great variety, though the guideline difference, different characteristics and the curative effect that all has separately of usage.
These medicines to be to attack, and make liver in damaged condition strengthen the metabolism burden, the medicine infringement liver and the immunologic function of heavy dose of, chronicity, in case drug withdrawal, the state of an illness " bounce-back " amount are greatly, even the state of an illness increases the weight of.Wherein some medicine has toxicity, side effect.
Summary of the invention:
The objective of the invention is in order to overcome above deficiency, provide a kind of nontoxic, have no side effect, harmless to liver, therapeutic effect is good, the wider treatment viral hepatitis of subject range, the medicine of liver cirrhosis disease.
The object of the present invention is achieved like this:
The medicine that the present invention treats viral hepatitis, liver cirrhosis disease comprises following component by weight:
The Radix Ginseng Rubra 1～4
Mushroom 5～9
Ganoderma 3～8
Cordyceps 1～3
Du. secondary 3～7
Oleum lini 6～10 can replace mushroom with the Lentinus Edodes of artificial culture, Lentinus Edodes etc., and its effect is basic identical.
Above-mentioned treatment viral hepatitis, the medicine of liver cirrhosis disease comprise following component by weight:
The Radix Ginseng Rubra 1～4
Mushroom 5～9
Ganoderma 3～8
Cordyceps 1～3
The Cortex Eucommiae 3～7
Oleum lini 6～10
Radix Scrophulariae 2～6
Fructus Jujubae 4～8
Huai wheat 5～10
Radix Glehniae 6～10
Colla Corii Asini 2～6
Ovum Gallus domesticus Flavus 2～5
Semen juglandis 6～10
Typhonium flagelliforme (Lodd.) Blume 1～5
Duck dried meat 6～12 therapeutic effect are good.
Above-mentioned treatment viral hepatitis, the medicine of liver cirrhosis disease comprise following component by weight:
The Radix Ginseng Rubra 2
Mushroom 8
Ganoderma 4
Cordyceps 2
Du. secondary 4
Oleum lini 8.5
Radix Scrophulariae 4
Fructus Jujubae 5
Huai wheat 8
Radix Glehniae 8
Colla Corii Asini 4
Ovum Gallus domesticus Flavus 3.5
Semen juglandis 8.5
Typhonium flagelliforme (Lodd.) Blume 2
Duck dried meat 10
Therapeutic effect is good.
The present invention treats Radix Ginseng Rubra in the medicine of viral hepatitis, liver cirrhosis disease, Ganoderma, Cordyceps, Ovum Gallus domesticus Flavus can strongly invigorating primordial QI, raise immunity; Pester antibiotic, be good for the stomach and spleen Typhonium flagelliforme (Lodd.) Blume dissipating blood stasis hemostasis, subduing swelling and relieving pain; Radix Glehniae, Radix Scrophulariae, YIN nourishing is supported liquid; The analgesic detoxification of oleum lini, suppressing the hyperactive liver be pleasant, control the skin Pruritus; Colla Corii Asini, Fructus Jujubae, semen juglandis tonifying the kidney to consolidate the essence, benefiting qi and nourishing blood, increase albumin, erythrocyte etc.; Duck dried meat YIN nourishing is supported lung, inducing diuresis to remove edema; Huai wheat, the Cortex Eucommiae, semen juglandis have the raising body immune function, short sugar, protein metabolism, contraction coronary vasodilator, cholesterol reducing effect; Modern medicine thinks that oleum lini, semen juglandis are rich in the necessary aminoacid of multiple human body such as linolenic and linoleic, cooperates the synthetic plant animal protein of duck dried meat.Medicine of the present invention is grown liquid with the strengthening the body resistance in the theory of Chinese medical science, yin nourishing, and raising and adjustment body's immunity combine together.For a large amount of hypertrophy of hepatocellular degeneration, necrosis and regeneration and liver inner tissue, cause liver structure disorder, distortion and quality hardening, the most effective stimulation body immune system opposing of hepatic insufficiency virus.Promote and adjust body's immunity, degraded liver cirrhosis disease collagen fiber are broken its helical structure, reach a large amount of outgrowth good efficacy of treatment because of hepatic necrosis and regenerating hepatic tissue.
Medicine of the present invention after concocting or handle according to the Pharmacopoeia of the People's Republic of China (1990 editions), directly is broken into the abundant mix homogeneously of powder before use.This medicated powder end is added the excipient adjuvant routinely and is made tablet and become pill, can become operational solid-state oral formulations.Medicine of the present invention also can be made into other dosage form.
With the 87 example treatments of medicine centering of the present invention, late period (losing the compensatory phase), liver cirrhosis disease patient (comprising posthepatitic cirrhosis, alcoholic cirrhosis, contain complication such as hepatic encephalopathy disease, upper gastrointestinal hemorrhage), Patients with Cirrhosis After Hepatitis 64 examples, the situation record of alcoholic cirrhosis patient 23 examples (wherein 26 examples esophagus fundus ventricularis varication occurs and break hemorrhagely, and 14 examples are with hepatic encephalopathy) is as follows:
1, check result before " two double " treatment
" two double " integrated mode: surface antigen positive, E-antigen positive, core antibody positive.(being commonly called as great three positive).
2, ultrasound diagnosis result:
1. not normal, the lobus dexter atrophy of liver, surface irregularity, edge indentation (or circle is blunt), in the liver echo obviously strengthen inhomogeneous, main portal vein broadening, portal vein left and right sides offshoot and trunk thromboembolism.
3, liver function test: albumin reduces, globulin raises, and albumin and globulin ratio are inverted, serum bilirubin 30-34 μ mol/L, and part is greater than 34 μ mol/L, and glutamate pyruvate transaminase and glutamic oxaloacetic transaminase, GOT raise.
4, above cirrhosis patients in decompensation (late period) disease patient treats January with medicine of the present invention (based on pill).Patients with Cirrhosis After Hepatitis " great three positive " changes surface antigen positive, E-antibody positive, core antibody positive (small three positive) into.Ultrasound diagnosis, the uneven joint joint shape that changes into of 73 routine liver surface, the edge becomes rough.15 routine ultrasound diagnosis change not quite in addition, and the portal vein embolization phenomenon partly is effectively controlled, and bleeding did not take place.12 examples hepatic encephalopathy do not occur and took place.Albumin raises, globulin reduces, serum bilirubin is reduced to below the 32 μ mol/L.
5, above patient is through Drug therapy of the present invention result's three months (course of treatment): patient's hepatitis B virus " great three positive ", change surface antigen positive, core antibody positive into.The liver table is by the uneven rough surface that changes into, and it is rough that the edge changes the edge into by zigzag.Albumin, globulin all are in normal value, and serum bilirubin is in normal value; Above-mentioned condition shows that posthepatitic cirrhosis disease patient virus replication is in and stops to duplicate or low-level replication status that the liver collagen fiber are effectively degraded, and the liver parenchyma reserve function recovers substantially.
Can affirm that thus it shows medicine of the present invention to posthepatitic cirrhosis disease, alcoholic cirrhosis disease curative effect: 1. nontoxic, have no side effect.2. improve and adjust body's immunity antiviral and fibrosis, recover liver reserve function.3. remove the blood vessel of intestinal bacteria, mediation obstruction, anti-hemorrhage and hepatic encephalopathy.
This shows that medicine of the present invention has significant superior curative effect for posthepatitic cirrhosis disease and alcoholic cirrhosis disease.Medicine of the present invention is applied widely.
The specific embodiment:
Medicine embodiment of the present invention sees Table 1:
Claims (3)
1, the medicine of treatment viral hepatitis, liver cirrhosis disease is characterized in that comprising by weight following component:
The Radix Ginseng Rubra 1～4
Mushroom 5～9
Ganoderma 3～8
Cordyceps 1～3
The Cortex Eucommiae 3～7
Oleum lini 6～10
2, the medicine of treatment viral hepatitis as claimed in claim 1, liver cirrhosis disease is characterized in that comprising by weight following component:
The Radix Ginseng Rubra 1～4
Mushroom 5～9
Ganoderma 3～8
Cordyceps 1～3
The Cortex Eucommiae 3～7
Oleum lini 6～10
Radix Scrophulariae 2～6
Fructus Jujubae 4～8
Huai wheat 5～10
Radix Glehniae 6～10
Colla Corii Asini 2～6
Ovum Gallus domesticus Flavus 2～5
Semen juglandis 6～10
Typhonium flagelliforme (Lodd.) Blume 1～5
Duck dried meat 6～12
3, the medicine of treatment viral hepatitis as claimed in claim 2, liver cirrhosis disease is characterized in that comprising by weight following component:
The Radix Ginseng Rubra 2
Dried mushroom 8
Ganoderma 4
Cordyceps 2
The Cortex Eucommiae 4
Oleum lini 8.5
Radix Scrophulariae 4
Fructus Jujubae 5
Huai wheat 8
Radix Glehniae 8
Colla Corii Asini 4
Ovum Gallus domesticus Flavus 3.5
Semen juglandis 8.5
Typhonium flagelliforme (Lodd.) Blume 2
Duck dried meat 10
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA031354785A CN1481876A (en) | 2003-07-25 | 2003-07-25 | Medication for virus hepatitis and hepatocirrhosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA031354785A CN1481876A (en) | 2003-07-25 | 2003-07-25 | Medication for virus hepatitis and hepatocirrhosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1481876A true CN1481876A (en) | 2004-03-17 |
Family
ID=34154654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA031354785A Pending CN1481876A (en) | 2003-07-25 | 2003-07-25 | Medication for virus hepatitis and hepatocirrhosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1481876A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102068569A (en) * | 2010-09-16 | 2011-05-25 | 北京绿源求证科技发展有限责任公司 | Traditional Chinese medicine for treating cirrhosis |
| CN101843877B (en) * | 2009-09-25 | 2011-11-23 | 北京绿源求证科技发展有限责任公司 | Chinese medicament for treating liver cirrhosis |
| CN102824600A (en) * | 2012-08-20 | 2012-12-19 | 王三元 | Pure traditional Chinese medicine preparation for nourishing liver, protecting liver, softening liver and shrinking spleen and preparation method thereof |
| CN104069173A (en) * | 2014-07-15 | 2014-10-01 | 延边利孚生物科技有限公司 | Medicine composition for treating hepatic diseases and preparation method thereof |
| CN106309696A (en) * | 2016-08-31 | 2017-01-11 | 刘晓东 | Traditional Chinese medicine composition for treating hepatitis and liver cirrhosis |
-
2003
- 2003-07-25 CN CNA031354785A patent/CN1481876A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101843877B (en) * | 2009-09-25 | 2011-11-23 | 北京绿源求证科技发展有限责任公司 | Chinese medicament for treating liver cirrhosis |
| CN102068569A (en) * | 2010-09-16 | 2011-05-25 | 北京绿源求证科技发展有限责任公司 | Traditional Chinese medicine for treating cirrhosis |
| CN102824600A (en) * | 2012-08-20 | 2012-12-19 | 王三元 | Pure traditional Chinese medicine preparation for nourishing liver, protecting liver, softening liver and shrinking spleen and preparation method thereof |
| CN102824600B (en) * | 2012-08-20 | 2014-07-23 | 王三元 | Pure traditional Chinese medicine preparation for nourishing liver, protecting liver, softening liver and shrinking spleen and preparation method thereof |
| CN104069173A (en) * | 2014-07-15 | 2014-10-01 | 延边利孚生物科技有限公司 | Medicine composition for treating hepatic diseases and preparation method thereof |
| CN106309696A (en) * | 2016-08-31 | 2017-01-11 | 刘晓东 | Traditional Chinese medicine composition for treating hepatitis and liver cirrhosis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1162171C (en) | Gynopathy treating traditional Chinese medicine | |
| CN1692939A (en) | Traditional Chinese medicine pill for treating hepatitis B, and its prepn. method | |
| CN1095674C (en) | Chinese medicinal composition for cerebrovascular disease, rheumatism and rheumatoid disease | |
| CN1895619A (en) | Chinese-medicinal composition for preventing and treating liver disease and its preparation | |
| CN1283309C (en) | Pure medicated wine | |
| CN1481876A (en) | Medication for virus hepatitis and hepatocirrhosis | |
| CN100340286C (en) | Medicine for treating hepatitis B and its preparing method | |
| CN1052889C (en) | Chinese proprietary for curing hepatitis | |
| CN1112194C (en) | Compound yexiazhu medicine and preparing process thereof | |
| CN1486736A (en) | Fibrillation-resisting liver softening bolus as compound Chinese medicine prepn for treating fibrillation and cirthosis of liver | |
| CN1294980C (en) | Medicine for treating liver disease | |
| CN1319587C (en) | Medicine powder for liver and spleen diseases | |
| CN1051471C (en) | Drug composition for curing osteoporosis | |
| CN1165335C (en) | Compound preparation for curing diarrhea | |
| CN107137455A (en) | A kind of pharmaceutical composition, preparation and purposes | |
| CN1059104C (en) | Capsule for anti hepatitis B | |
| CN1186044C (en) | Chinese medicine 'lidandishi' for treating hepatobiliary calculus and cholecystitis | |
| CN1059117C (en) | Katsutoxin pill for tumor and preparing method thereof | |
| CN1103796A (en) | Dressing medicine for treating hyperosteogeny and the prepn. method | |
| CN100515477C (en) | Chinese medicine decoction for treating prolapse of lumber intercertebtral disc | |
| CN1173718C (en) | Medicine for curing lupus erythematosus etc. immune diseases induced diseases | |
| CN1190229C (en) | Medicine for curing hepatitis B | |
| CN1235635C (en) | Medicine for treating osteosis | |
| CN1150015C (en) | Medicine for treating leucocytopenia caused by lupus erythematosus | |
| CN1281251C (en) | Medicine for treating chronic hepatitis and liver cirrhosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |